Forecast: Diabetes Medicine Sales in Finland

Between 2013 and 2023, diabetes medicine sales in Finland have shown steady growth, increasing from 131.0 million euros to 196.9 million euros. The year-on-year variation reveals fluctuations, such as a dip in 2017 where sales declined by 3.58%, followed by consistent annual growth rates peaking at 5.95% in 2020. Recent years indicate a stable upward trend with a 4.24% increase in 2023, and a CAGR of 4.92% over the previous five years.

Looking forward, from 2024 to 2028, sales are forecasted to continue growing, albeit at a slightly lower average annual rate of 2.77%, culminating in an anticipated increase of 14.66% over this period. The estimated value for 2028 is 234.7 million euros.

Future trends to watch for:

• Advancements in diabetes technology and medicine that could accelerate market expansion.
• Potential impacts of healthcare policy changes and reimbursement schemes on market demand.
• Increasing prevalence of diabetes in Finland and its effects on market dynamics.
• Adoption rates of innovative treatments and their impact on the sales of traditional diabetes medicines.